Ephedrine
(1R,2S)-2-(methylamino)-1-phenylpropan-1-ol
Overview
Ephedrine belongs to Stimulants.
Effects
Dosing & duration
Not reported
Dose ranges
Duration
Chemical & Physical Properties
| Formula | C10H15NO |
| Molar mass | 165.23 g/mol |
| State | Solid |
| Melting point | 34 °C |
| Boiling point | 255 °C |
| Density | 1.0085 g/cm³ at 22 °C |
| Vapor pressure | Not reported |
| pKa | 9.61 |
| LogP | 1.13 |
| Solubility | Very soluble in water (~56,900 mg/L at 25 °C, 63,600 mg/L at 30 °C), Soluble in oils |
| Refractive index | Not reported |
Identifiers & Synonyms
| CAS | 299-42-3 |
| CAS (enantiomer) | |
| PubChem CID | 9294 |
| InChIKey | KWGRBVOPPLSCSI-WPRPVWTQSA-N |
| InChI | InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1 |
| SMILES | CN[C@@H](C)[C@H](O)c1ccccc1 |
Synonyms
- L-ephedrine
- (−)-ephedrine
- Ephedrine hydrochloride
Pharmacodynamics & Biochemistry
Ephedrine is a naturally occurring sympathomimetic alkaloid (from Ephedra / má huáng) and a mixed-acting amine. It works mainly indirectly: taken up into noradrenergic nerve terminals by the norepinephrine transporter, it displaces norepinephrine from storage vesicles into the synapse, raising adrenergic tone throughout the body: its most potent measured action is as a norepinephrine-transporter (NET) substrate (EC50 ≈50 nM), with weaker substrate activity at the dopamine transporter. Direct receptor activity is comparatively negligible: a receptorome screen found only weak binding at α2-adrenergic and 5-HT7 receptors (Ki ≈1–10 µM) and no meaningful α1- or β-adrenoceptor activity, so its sympathomimetic effects are essentially all indirect, via the noradrenaline it releases. Because release rather than direct receptor potency drives the effect, tolerance (tachyphylaxis) develops as vesicular stores deplete. The result is a broad sympathomimetic profile: α1-mediated vasoconstriction raises blood pressure and shrinks nasal mucosa (decongestion). β1 stimulation increases heart rate and cardiac output. β2 stimulation relaxes bronchial smooth muscle (bronchodilation). It crosses into the CNS and is a mild stimulant: less potent and less euphoric than amphetamine, to which it is structurally related and for which it is a synthesis precursor. The medicinal drug is the (1R,2S)-(−)-erythro isomer (L-ephedrine). Its diastereomer pseudoephedrine (1S,2S) shares the peripheral decongestant use but has weaker central and pressor effects. Ephedrine is largely excreted unchanged by the kidneys, so its clearance depends on urine pH: acidic urine speeds elimination and shortens its action.
Biological targets
- NET
- Adrenergic system
Binding & functional measurements
| Target | Measurement | Species |
|---|---|---|
| Norepinephrine transporter | pEC50 7.3 | Human |
| β2-adrenoceptor | pKi 5.6 | Human |
| α2-adrenoceptor | pKi 5.5 | Human |
| 5-HT7 receptor | pKi 5.5 | Human |
Pharmacokinetics
| Bioavailability | ≈85–90% oral |
| Tmax | ≈1–2 h (oral), onset 15–60 min oral, seconds IV |
| Half-life | ≈3–6 h (shorter in acidic urine) |
| Vd | Not reported |
| Protein binding | ≈24–29% |
| Metabolism | Minimal hepatic (N-demethylation, oxidative deamination) |
| Excretion | Mainly renal, ~55–75% unchanged. Strongly urine-pH dependent |
Toxicology & Safety
Not reported
Ephedrine is a potent cardiovascular stimulant with a narrow margin between its therapeutic and toxic effects. Common effects are a raised heart rate and blood pressure, palpitations, tremor, anxiety, insomnia, headache and urinary retention. Higher doses can cause dangerous hypertension, tachyarrhythmias, myocardial infarction, stroke, seizures and stimulant psychosis. Risk rises sharply when it is combined with other stimulants: the ephedrine + caffeine ('ECA') combination popular for weight loss and 'energy' markedly increases cardiovascular strain, and combining it with an MAO inhibitor can trigger a hypertensive crisis. Deaths linked to ephedra/ephedrine weight-loss supplements led the US FDA to ban them in 2004. It should be avoided in people with heart disease, hypertension, hyperthyroidism, phaeochromocytoma or closed-angle glaucoma.[2]
Legal Status
US: OTC (restricted). UK: Pharmacy medicine. DE: Prescription only (Rx)
Interactions & Contraindications
Drug interactions
Contraindications
No interactions or contraindications listed.
Usage & Context
- Therapeutic.
- Research.
Sources & Evidence
- PubChem: Ephedrine / (1R,2S)-(−)-ephedrine (CID 9294) — identifiers & experimental properties
- Wikipedia: Ephedrine — pharmacology, pharmacokinetics, medical use, interactions & legal status CC BY-SA 4.0
- IUPHAR/BPS Guide to PHARMACOLOGY: ephedrine (ligand 556) — β2-adrenoceptor data CC BY-SA 4.0
- FDA / DailyMed: Ephedrine prescribing information — pharmacokinetics & metabolism
- Rothman RB, Vu N, Partilla JS, et al. (2003). In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther 307:138-45.
PMID 12954796 · doi:10.1124/jpet.103.053975
- January B, Seibold A, Whaley B, et al. (1997). beta2-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists. J Biol Chem 272:23871-9.
PMID 9295336 · doi:10.1074/jbc.272.38.23871